Some outside researchers were less reserved. Clinical trials using CRISPR gene editing have been underway for nearly a decade. But like most trials, they focused on broad groups of patients.

Shares of CRISPR Therapeutics (NASDAQ:CRSP) can't seem to catch a break, now down close to 8% year to date and more than 80% ...

The BRILLIANCE study of EDIT-101 in Leber congenital amaurosis type 10 (LCA10) – an inherited form of blindness – was reported to be the first 'in vivo' CRISPR/Cas9 medicine to be administered ...

The CRISPR specialist said that a single 50mg infusion of NTLA-2002 – which switches off a gene involved in the potentially life-threatening inflammatory attacks that characterise HAE ...

CRISPR-Cas9 genome editing exploits the CRISPR-Cas system to modify a genome in a targeted manner. Guided by RNA, the Cas9 endonuclease breaks DNA at a target sequence. Imprecise repair of the ...

CRISPR-based technologies have taken the world by storm thanks to the technique’s ability to edit nucleic acids. Today, researchers are not only working to understand how to better harness the ...

Collaborating with CRISPR-Cas9 co-inventor Jennifer Doudna and Jill Banfield at UC Berkeley, Steven Jacobsen, a distinguished professor of molecular, cell and developmental biology at UCLA ...